Literature DB >> 20175038

Hepatocellular carcinoma and hepatic adenocarcinosarcoma in a patient with hepatitis B virus-related cirrhosis.

Qian Zhao1, Chang-Qing Su, Hui Dong, Xin-Yuan Lu, Meng-Chao Wu, Wen-Ming Cong.   

Abstract

The authors present the case of a 48-year-old man with hepatitis B cirrhosis, who developed two primary malignant liver tumors that were morphologically distinct from each other. The first tumor was a hepatocellular carcinoma and the second tumor, detected 17 months later was a hepatic carcinosarcoma with cholangiocarcinomatous and sarcomatous components, without any hepatocellular carcinoma component. Clonality studies using microsatellite-based loss of heterozygosity (LOH) demonstrated different LOH patterns existed between the hepatocellular carcinoma and the hepatic carcinosarcoma, indicative of different clonal origins. The authors discuss the histogenesis, histopathologic diagnosis, and clinical behavior of hepatic carcinosarcoma.

Entities:  

Mesh:

Year:  2010        PMID: 20175038     DOI: 10.1055/s-0030-1247137

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  3 in total

Review 1.  Carcinosarcoma of the liver: report of a case.

Authors:  Takatsugu Yamamoto; Yukiko Kurashima; Kazunori Ohata; Ryoya Hashiba; Shogo Tanaka; Takahiro Uenishi; Koichi Ohno; Takashi Ikebe; Katsuhiko Miyaji; Nobusuke Fukumoto
Journal:  Surg Today       Date:  2013-05-05       Impact factor: 2.549

2.  Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.

Authors:  Qian Zhao; Wen-Long Yu; Xin-Yuan Lu; Hui Dong; Yi-Jin Gu; Xia Sheng; Wen-Ming Cong; Meng-Chao Wu
Journal:  Chin J Cancer       Date:  2016-08-24

Review 3.  Primary carcinosarcoma of the liver: imaging features and clinical findings in six cases and a review of the literature.

Authors:  Jing Li; Pan Liang; Dandan Zhang; Jie Liu; Hongkai Zhang; Jinrong Qu; Jianbo Gao
Journal:  Cancer Imaging       Date:  2018-02-27       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.